Monthly Archives: April 2018
-
- April 04, 2018
Cancer immunotherapy is one promising cancer treatment option whereby the host's own immune system is used to treat cancer. The therapy works by either stimulating certain immune activities, or counteracting cancer cell signals that suppress immune responses. Cancer immunotherapy has progressed significantly since 2011, when the first immune checkpoint inhibitor was approved by the US Food and Drug Administration (FDA). To date, the FDA has approved 6 immune checkpoint inhibitors with more on the way for the treatment of various cancer types including melanoma, lung cancer and lymphoma. Furthermore, in 2017, the FDA approved 2 chimeric antigen receptor T-cell (CAR-T) therapies to treat acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Cancer immunotherapy Origins
The first recorded attempt at cancer immunotherapy can be traced back to more than a century ago. In 1891, William Bradley Coley (1862-1936), a 29-year-old bone surgeon
Recent Posts
